AbbVie Receives Positive CHMP Opinion for Crohn’s Disease Treatment

News
Article

CHMP recommended the approval of AbbVie’s RINVOQ (upadacitinib) as a treatment for adults with moderate-to-severe Crohn’s disease.

AbbVie announced on Feb. 27, 2023 that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of RINVOQ (upadacitinib) for the treatment of Crohn’s disease. The indication would be as a 45-mg induction dose, followed by maintenance doses of 30 or 15 mg, in adult patients with moderate-to-severely active symptoms who have had an inadequate response, lost response, or who were intolerant to conventional therapy or a biologic agent.

Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor. According to a company press release, in human cellular assay, upadacitinib functions by preferentially inhibiting signaling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2.

Data from two induction studies (U-EXCEED and U-EXCEL) and one maintenance study (U-ENDURE) was submitted in support of this indication. Across all three Phase III studies, patients treated with upadacitinib achieved the co-primary endpoints of clinical remission per stool frequency/abdominal pain and endoscopic response compared to placebo. Additional Phase III trials in Crohn’s disease, as well as trials treating giant cell arteritis and Takayasu arteritis, are ongoing.

"The recent CHMP recommendation to approve upadacitinib for use in Crohn's disease is a momentous step, bringing us closer to offering a first-of-its-kind, once-daily oral treatment that can make a difference for people living with this disease," said Roopal Thakkar, senior vice-president, Development, Regulatory Affairs, and chief medical officer, AbbVie. "We remain steadfast in our commitment to researching and developing treatment options as part of a diverse portfolio of therapies for those living with inflammatory bowel diseases."

Source: AbbVie

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes